(Q28251965)

12 December 2020

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

12 December 2020

Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial.

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

1 reference

12 December 2020

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

1 reference

12 December 2020

A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis.

1 reference

12 December 2020

Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR.

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

12 December 2020

Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study

1 reference

12 December 2020

1 reference

12 December 2020

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients

1 reference

12 December 2020

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

12 December 2020

Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis

1 reference

12 December 2020

The diagnosis of primary progressive multiple sclerosis

1 reference

12 December 2020

Primary progressive multiple sclerosis: a 5-year clinical and MR study.

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

Major differences in the dynamics of primary and secondary progressive multiple sclerosis

1 reference

12 December 2020

In search of a disease marker: the cytokine profile of primary progressive multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

1 reference

12 December 2020

MS functional composite: relation to disease phenotype and disability strata

1 reference

12 December 2020

Glutamate excitotoxicity in a model of multiple sclerosis

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

12 December 2020

Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients

1 reference

12 December 2020

Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK.

1 reference

12 December 2020

Management of multiple sclerosis: current trials and future options

1 reference

12 December 2020

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

12 December 2020

Remyelination in multiple sclerosis

1 reference

12 December 2020

Diagnostic criteria for primary progressive multiple sclerosis: a position paper

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

12 December 2020

Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study

1 reference

12 December 2020

Primary and transitional progressive MS: a clinical and MRI cross-sectional study.

1 reference

12 December 2020

Spinal cord atrophy and disability in multiple sclerosis

1 reference

12 December 2020

Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group

1 reference

12 December 2020

Kurtzke scales revisited: the application of psychometric methods to clinical intuition

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

1 reference

12 December 2020

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1 reference

12 December 2020

Symptomatic management and rehabilitation in multiple sclerosis.

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

1 reference

12 December 2020

A comparison of the pathology of primary and secondary progressive multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Scales for rating impairment in multiple sclerosis: a critique.

1 reference

12 December 2020

Axonal transection in the lesions of multiple sclerosis

1 reference

12 December 2020

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

12 December 2020

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

1 reference

12 December 2020

Axonal damage in acute multiple sclerosis lesions.

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Progressive cerebral atrophy in multiple sclerosis. A serial MRI study.

1 reference

12 December 2020

The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study

1 reference

12 December 2020

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

12 December 2020

Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms.

1 reference

12 December 2020

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

1 reference

12 December 2020

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

1 reference

12 December 2020

In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis.

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis.

1 reference

12 December 2020

Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis.

1 reference

12 December 2020